Evaluation of Volatile Organic Compounds in Mepolizumab Therapy

Status Not yet recruiting

Clinical Trial Summary

This study will recruit patients who are being prescribed Mepolizumab as part of their standard clinical care for the treatment of severe eosinophilic asthma. Over the course of their treatment, research data (questionnaires) and research samples (blood, breath and urine) will be collected in parallel to standard clinical measurements. The data and samples will be investigated to help better understand how Mepolizumab works, why it doesn't work in certain patients and why it works very well in others. This will help prescribers better identify patients that will benefit from Mepolizumab.

Clinical Trial Description

EVOC4M is a prospective observational study investigating Mepolizumab in the treatment of severe eosinophilic asthma. This study will recruit patients receiving Mepolizumab as part of their standard clinical care in an NHS commissioned Specialised Adult Severe Asthma Service. Over the course of their treatment, research data (questionnaires) and research samples (blood, breath and urine) will be collected in parallel to standard clinical measurements. Clinical studies have demonstrated blood eosinophil levels to be predictive of the magnitude of the impact of Mepolizumab in reducing severe disease exacerbations but it is appreciated that there are still treatment failures despite this selection criteria. Clinical decision and policymaking are increasingly concerned by the health economic implications of these high-cost therapies and so clinical biomarkers are now being sought for theragnostics: prediction of treatment response The study will try to identify biomarkers that will can discriminate between those that respond to Mepolizumab ("responders") and those that do not ("non-responders"). This will improve our understanding of how Mepolizumab works. In particular, the investigators are interested in exhaled volatile organic compounds (VOCs), which are measured in exhaled breath samples. Exhaled breath is safe and easy to collect and has direct contact with the organ of interest, the airways. A VOC biomarker that predicts Mepolizumab success may translate to clinical practice. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04924478
Study type	Observational
Source	University Hospital Southampton NHS Foundation Trust
Contact	Adnan Azim
Phone	02381204479
Email	a.azim@soton.ac.uk
Status	Not yet recruiting
Phase
Start date	July 2021
Completion date	December 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04742504` - Interaction Between Benralizumab and Basophils in Eosinophilic Asthma
Recruiting	`NCT04565483` - Predictive Signature of Benralizumab Response	Phase 4
Completed	`NCT04181190` - Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients
Recruiting	`NCT05787678` - Dupilumab Efficacy on Bronchial Inflammation, Small Airways Disfunction and Mucous Secretion
Completed	`NCT04456270` - Asthma Control in a Dutch Primary Care Population
Not yet recruiting	`NCT05091385` - Efficacy of Mepolizumab in Polish Patients With Severe Eosinophilic Asthma
Recruiting	`NCT05078281` - Patients With Severe Eosinophilic Asthma Treated With Benralizumab
Recruiting	`NCT04512521` - Functional Lung MRI for Early Treatment Response Assessment for Patients With Eosinophilic Asthma
Recruiting	`NCT05813288` - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)	Phase 3
Recruiting	`NCT04319705` - Anti-viral Effects of Azithromycin in Patients With Asthma and COPD	Phase 4
Recruiting	`NCT06288516` - BenRalizumab Effect on Airway Remodeling in Severe asTHma	Phase 4
Active, not recruiting	`NCT03733535` - Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI	N/A
Not yet recruiting	`NCT05241769` - The Influence of Inhaled CorticoSteroids Adherence on Treatment Response to Mepolizumab in Severe Eosinophilic Asthma
Not yet recruiting	`NCT05404763` - Mepolizumab and Physical Activity in Severe Asthma
Recruiting	`NCT05763121` - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.	Phase 3
Recruiting	`NCT05748600` - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma	Phase 3
Completed	`NCT03453021` - Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma
Active, not recruiting	`NCT04612556` - Efficacy of Mepolizumab in Severe Asthmatics on a Long Term (MESILICO)
Completed	`NCT04710134` - Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma	Phase 4
Not yet recruiting	`NCT05144087` - The Influence of Mepolizumab on Structural and Inflammatory Cells in Severe Eosinophilic Asthma

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Evaluation of Volatile Organic Compounds in Mepolizumab Therapy — EVOC4M

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms